REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/13/2026
Back to search
Official data from USPTO
ENOVACHEM PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
06/14/2026
Trademark type
Combined
Nice classes
5, 40
Filing date
09/02/2015
Registration date
06/13/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/11/2023
Last transaction
06/14/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/13/2015
First use in commerce
04/05/2016
Drawing code
3
Owner type
03
Owner location
Torrance, CA, US
Examiner
COLLIER, DAVID E
Law office
L90
Current location
TMEG LAW OFFICE 109
Mark description
The mark consists of a stylized drawing of a white square with chevron insignias on each of the outer corners of the square; the chevrons are in one half color light blue and the other half in dark blue, with the word "Enovachem" to the right of the square in dark blue, and then the word "PHARMACEUTICALS" directly underneath in light blue.
Holders and representatives
Holders
Asclemed USA, Inc.
Representatives
Irene Y. Lee Russ, August & Kabat
Technical classification
Nice Classes
Class 5Class 40
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropsliquid vialsmedicinal preparationsfor prevention of flufor relief of headachesprevention of anemiaprevention of peripheral neuropathyfor use as an anestheticfor use as an anti-inflammatoryfor treatment of incomplete or infrequent bowel movements; Medicinal preparationscreamsgels for physicians' ready useibuprofen cream and cyclobenzaprine cream for treatment of inflammationpain and burn for skin diseases and for treatment of pain and stiffness caused by muscle spasms; Medicinal kits comprised of pillstabletscapsulescapletsliquid dropsliquid vialsmedicinal preparations for prevention of the flufor relief of headachesprevention of anemiaprevention of peripheral neuropathyfor use as an anestheticfor use as an anti-inflammatoryfor treatment of incomplete or infrequent bowel movements; nutritional supplements; facial treatment preparations for scars
Class 40
Custom manufacturing of prescription and non-prescription medicinesnutritional supplementsfacial treatment for scardrugscontrolled substances for physicianspharmaciesmanufacturerswholesalersdistributors
Publications
History of USPTO decisions and trademark events.
38 publications found
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
01/11/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/11/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/11/2023
E815
TEAS SECTION 8 & 15 RECEIVED
06/27/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/13/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/13/2017
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/06/2017
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/05/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
05/05/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/05/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
05/05/2017
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
05/05/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/18/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/11/2016
GNRT
NON-FINAL ACTION E-MAILED
11/11/2016
CNRT
SU - NON-FINAL ACTION - WRITTEN
11/11/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/24/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/24/2016
IUAF
USE AMENDMENT FILED
10/07/2016
EISU
TEAS STATEMENT OF USE RECEIVED
10/07/2016
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/23/2016
EX1G
SOU EXTENSION 1 GRANTED
09/21/2016
EXT1
SOU EXTENSION 1 FILED
09/21/2016
EEXT
SOU TEAS EXTENSION RECEIVED
09/21/2016
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/26/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/01/2016
PUBO
PUBLISHED FOR OPPOSITION
03/01/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/10/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/21/2015
XAEC
EXAMINER'S AMENDMENT ENTERED
12/21/2015
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/21/2015
GNEA
EXAMINERS AMENDMENT E-MAILED
12/21/2015
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/21/2015
DOCK
ASSIGNED TO EXAMINER
12/15/2015
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/09/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/08/2015
NWAP
NEW APPLICATION ENTERED
09/05/2015
Continuous trademark protection
Get notified about every new filing that threatens ENOVACHEM PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.